Fluticasone Propionate
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Fluticasone Propionate
Fluticasone Propionate: Known uses and market status in Australia
Summary
The TxGNN deep-learning model produced candidates for Fluticasone Propionate, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The two known uses listed below are recorded as relations in the knowledge graph.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| atopic eczema |
| dermatitis, atopic |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14347D | Flixotide | Pressurised inhalation containing flutic | Valid |
Safety Considerations
- Contraindications (TxGNN model associations, not label text): The TxGNN model (deep learning) associates fluticasone propionate with the following conditions. These associations may reflect similarities the model learned between related diseases, not biological evidence, and should be checked against the Product Information:
- Cardiovascular: hypertension, long QT syndrome (including the familial form)
- Other systemic: epilepsy, liver disease, gallbladder disease, hyperglycaemia
- Infection-related: measles, herpes simplex virus keratitis
- Pituitary and endocrine: hypopituitarism, pituitary hormone deficiencies (including Sheehan syndrome), growth hormone deficiency, hypogonadotropic hypogonadism and Kallmann syndrome
- Drug interactions: No drug-drug interaction records were returned. The pharmacology records show binding to the glucocorticoid, mineralocorticoid and progesterone receptors.
- Guardrails from the atopic dermatitis evidence: Monitor for HPA axis suppression and skin atrophy with extensive or prolonged use, particularly in children. Use intermittent or maintenance regimens as studied.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.